The Predictive Role of <i>PIK3CA</i> Mutation Status on <i>PI3K</i> Inhibitors in <i>HR+</i> Breast Cancer Therapy: A Systematic Review and Meta-Analysis

<div>Hazard ratio for progression-free survival (PFS) in the <i>PIK3CA</i>-mutated group and the <i>PIK3CA</i> wild-type group.</div>

BioMed Research International

fig3

Figure 3

Figure 3: The Predictive Role of <i>PIK3CA</i> Mutation Status on <i>PI3K</i> Inhibitors in <i>HR+</i> Breast Cancer Therapy: A Systematic Review and Meta-Analysis 

BioMed Research International

The Predictive Role of PIK3CA Mutation Status on PI3K Inhibitors in HR+ Breast Cancer Therapy: A Systematic Review and Meta-Analysis

Figure 3